✦ LIBER ✦

PCN4 COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER

✍ Scribed by J Ryan; M Hirsch; H Knight

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN35 A COST UTILITY ANALYSIS OF FULVEST

✍ M Pangali; A Christodoulopoulou; A Ardavanis; V Barbounis; E Galani; D Skarlos 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Fulvestrant versus anastrozole as second

✍ I Vergote 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 68 KB

A comparison of fulvestrant and the thir

✍ David Dodwell; Ignace Vergote 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 317 KB

Exemestane may be as effective as tamoxi

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

PCN6 A COST-EFFECTIVENESS ANALYSIS OF AD

✍ J Mould-Quevedo; J Tapia-Valencia; G Davila-Loaiza 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

PCN23 COST-EFFECTIVENESS ANALYSIS OF LAP

✍ F Ejzykowicz; JW Hay 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB